PLGA

Nanoprecipitation

Doxorubicin

BSA

MDA-MB-231

230

−45

[96]

PLGA

Emulsion-solvent evaporation

Indocyanine green, Doxorubicin

PVA

-

(137 ± 2) - (164 ± 2)

(−9.9 ± 0.4) - (−12.3 ± 0.1)

[97]

PLGA

Nanoprecipitation

Curcumin

PVA

A2780CP, MDA-MB-231

(76.2 ± 5.36) - (560.4 ± 10.95 )

(−0.06 ± 0.01) - (0.06 ± 0.01)

[98]

PLGA

Emulsion-solvent evaporation

Docetaxel, Poloxamer 188

PVA

MCF-7, TAX30

(217.6 ± 8.6) - (274.7 ± 4.1)

(−23.35 ± 1.17) - (−41.28 ± 2.89)

[99]

PLGA

Emulsion-solvent evaporation, Salting-out

Vincristine, Verapamil

PVA

MCF-7, MCF-7/ADR

98.8 ± 8.4

−0.75 ± 0.12

[100]

PLGA

Nanoprecipitation

Hypericin

PVA

NuTu-19

210.3 - 268.9

(−3.7) - (−7.9)

[101]

PLGA

Solvent diffusion (Nanoprecipitation)

Paclitaxel

PVA

C6 glioma

169.3 ± 4.16) - (182.8 ± 3.78)

(−3.45 ± 0.58) - (−11.72 ± 2.27)

[102]

PLGA

Solvent extraction/ evaporation

Paclitaxel

PVA, Vitamin E TPGS

HT-29

293.6 ± 4.8, 235.7 ± 14.8

−26.05, −35.60

[103]

PLGA

High pressure homogenization

Paclitaxel

PVA

C6 glioma

(245.0 ± 20.4) - (305.4 ± 10.6)

-

[104]

PLGA

Nanoprecipitation

Sialic acid, N-acetylneuraminic acid

Pluronic F68, Polysorbate 80

CD14+ human monocytes

(63 ± 5) - (190 ± 16)

(−23 ± 3) - (−38 ± 3)

[105]

PLGA

Solvent injection

Aromatase inhibitor

-

SKBR-3

170.3 ± 7.6

−18.9 ± 1.5

[106]

PLGA

Emulsion-solvent evaporation

Paclitaxel

-

Ch-hep-3

(119 ± 6.2) - (129 ± 5.2)

(−4.6 ± 0.3) - (−31.5 ± 1.2)

[107]

PLGA

Double emulsion-solvent diffusion

BSA

PVA

MCF-7, MCF-10A neoT, Caco-2

320 - 360

−25

[108]

PLGA

Single emulsion solvent evaporation

Rapamycin

PVA

MCF-7

274 ± 1.6

−13.8 ± 5.1

[109]

PLGA

Modified solvent extraction/ evaporation

Paclitaxel

PVA

Caco-2, SK-BR-3

(293.8 ± 5.7) - (312.3 ± 8.2)

(−35.07 ± 1.68) - (−21.24 ± 2.11)

[110]

PLGA

Double emulsion-solvent diffusion

PE38KDEL, a 38 kDa mutant form of Pseudomonas

exotoxin A

PVA

D2F2/E2,

SK-BR3, D2F2

(108.3 ± 13.9) - (124.2 ± 21.2)

(−36 ± 5) - (12 ± 7)

[111]

PLGA

Emulsion-solvent extraction/ evaporation

Rhodamine

PVA

HEK293, TE671

(400 ± 100) - (550 ± 90)

(−0.96 ± 0.01) - (−2.9 ± 0.2)

[112]

PLGA

Emulsion-solvent evaporation/ extraction

FITC-TT peptide, DQ-BSA

PVA

Granulocytes, PBMCs

202 ± 4, 239 ± 14

(−28.6 ± 0.4), (−44.9 ± 1.8)

[113]

PLGA

Double emulsion-solvent evaporation

siRNA

PVA

DCs

350 - 390

(−13) - (−19)

[114]

PLGA

Double emulsion-solvent evaporation

-

PVA

DCs

(328 ± 30) - (511 ± 26)

(−25) - (−46.4)

[115]

PLGA

Solvent evaporation

Rapamycin, TMRD Dextran

PVA

DCs

150 - 450

-

[116]

PLGA, PLA

Emulsion-solvent evaporation

Dexamethasone, Futamide

PVA

240, 270

19 to 28

[117]

PLGA, PLA

Double emulsion-solvent evaporation

BSA, Coumarin-6

PVA

VSMCs, HASMCs, HA-VSMCs

69 - 98

(−5.3) - (−23)

[118] - [120]

PLGA, PLGA-PEG

Solvent diffusion

Conjugated cyclo(1,12)PenITDGEATDSGC (cLABL) peptide

PEMA

HUVEC

177 ± 11, (202 ± 11) - (268 ± 19)

−40.2 ± 3.7, (−31.4 ± 4.0) - (−8.3 ± 0.9)

[121]

PLGA, PS

Emulsion-solvent extraction/ evaporation

Coumarin-6

PVA, Vitamin E TPGS

Caco-2

(261.6 ± 9) - (295.4 ± 15), 50 - 500

(−36.76) - (18.38)

[27]

PLGA-PEG

Nanoprecipitation

Avidin, Streptavidin, Neutravidin, Coumarin-6

-

N18-RE-105, b.End3, HepG2

(111.1 ± 1.8) - (255.2 ± 6.3)

(−0.497 ± 0.402) - (−32.07 ± 3.19)

[122]